Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Bispecific t-cell receptor therapy

20 evidence topics · 14 sources

Tebentafusp: IMCgp100-202 primary analysis of overall survival in the intention-to-treat population of 378 participants
Tebentafusp: IMCgp100-202 overall survival, progression-free survival, and response in the 3-year analysis

“In this 3-year analysis, the overall survival benefit continued to favor tebentafusp, with a stratified hazard ratio for death of 0.68 (95% CI, 0.54 to 0.87) (Fig. 1A). Median overall survival was 21.6 months (95% CI, 19.0 to 24.3) in the tebentafusp group and 16.9 months (95% CI, 12.9 to 19.5) in the control group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The percentage of patients who were surviving at 1, 2, and 3 years among those treated with tebentafusp was 72%, 45%, and 27%, respectively, as compared with 60%, 30%, and 18% among the patients in the control group (Fig. 1A and Table S4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Median progression-free survival was 3.4 months (95% CI, 3.0 to 5.4) in the tebentafusp group and 2.9 months (95% CI, 2.8 to 3.0) in the control group (stratified hazard ratio for progression or death, 0.76; 95% CI, 0.60 to 0.97) (Fig. 1B and Table S4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“With extended follow-up, the percentage of patients who had an objective response continued to be higher in the tebentafusp group than in the control group (11% vs. 5%), with five additional patients in the tebentafusp group having a partial response since the previous analysis (Table 1 and Fig. S5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Tebentafusp: IMCgp100-202 survival with progression on tebentafusp and treatment beyond radiographic progression at 5 years

“After adjusting for covariates, a post hoc analysis showed that patients who were treated with tebentafusp beyond radiographic progression had longer overall survival than those who discontinued treatment.” (opens the source at this quote in a new tab)

“Overall survival in patients with a best overall response of progressive disease by day 100 after randomization continued to be longer in the tebentafusp group than in the control group after a minimum duration of follow-up of 5-years [hazard ratio 0.61 (95% CI 0.43-0.88)” (opens the source at this quote in a new tab)

“Although the effect of TBP cannot be determined with certainty in this study, after adjusting for differences in these covariates, continued tebentafusp treatment was associated with improved postprogression survival [hazard ratio 0.61 (95% CI 0.44-0.83); Figure 5], with a similar trend of benefit among patients whose best overall response was progressive disease [hazard ratio 0.67 (95% CI 0.44-1.01)].” (opens the source at this quote in a new tab)

“Additionally, after rebaselining tumor burden at the point of initial disease progression, 27% (38/139) of tebentafusp patients treated beyond PD had subsequent tumor reduction compared with only 4% (1/28) of patients in the control group.” (opens the source at this quote in a new tab)

“Notably, 22% of patients in the control group received subsequent tebentafusp.” (opens the source at this quote in a new tab)

Cytokine release syndrome: management with antipyretics, fluids, and corticosteroids, and hospitalization in IMCgp100-202

“Unlike other trials of T-cell engagers, none of the three tebentafusp trials mandated any premedications as primary prophylaxis for CRS. The medications most frequently used to treat CRS were antipyretics (88%), intravenous fluids (45%), and systemic corticosteroids (25%; Table 3); four (1%) patients received tocilizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Most patients with CRS (64%) received only a single dose of systemic corticosteroid to manage their CRS episodes, and in a post hoc propensity score analysis of IMCgp100-202, early corticosteroid use to manage AE did not negatively affect OS when adjusted for baseline prognostic factors (Fig. 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In a retrospective analysis of hospitalizations, defined as either an extension of the mandated monitoring period during intra-patient dose escalation or an unplanned hospitalization at any time, in IMCgp100-202, a similar percentage of patients experienced an SAE-related hospitalization in the tebentafusp arm (24%) as in the investigator’s choice control arm (23%; Supplementary Table S8). In the tebentafusp group, most (65%) SAE-related hospitalizations occurred during the intra-patient dose-escalation period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Tebentafusp: CADTH recommendation, clinical findings, and inpatient monitoring for initial doses

“The CADTH pCODR Expert Review Committee (pERC) recommends that tebentafusp be reimbursed for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM) in the first-line setting” (opens the source at this quote in a new tab)

“Tebentafusp was associated with a risk of cytokine release syndrome and dermatological adverse events. pERC acknowledged that while not insignificant, these adverse events are transient and manageable with monitoring in an inpatient setting for initial doses, supportive care, and dose adjustment.” (opens the source at this quote in a new tab)

“According to the clinical expert consulted by CADTH, the first 3 to 4 infusions of tebentafusp are associated with a risk of cytokine release syndrome which requires inpatient monitoring in an experienced institution and management by a specialist physician experienced in the use of tebentafusp. Subsequent infusions may be performed in community clinic setting.” (opens the source at this quote in a new tab)

“pERC discussed the indirect treatment comparison (ITC) submitted by the sponsor: an unanchored matching-adjusted indirect comparison (MAIC) of tebentafusp relative to ipilimumab plus nivolumab. pERC noted that while a statistically significant improvement in OS and progression-free survival (PFS) for tebentafusp was demonstrated, the results of the ITCs stem from highly uncertain evidence due to limitations that impact the internal and external validity, despite the various adjustments.” (opens the source at this quote in a new tab)

“The preparation of tebentafusp is complex and intense and will require considerable Pharmacy resources to prepare each dose.” (opens the source at this quote in a new tab)